Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience
Authors:
- U. OkazakiUOU. Okazaki
- I. NakayamaINI. Nakayama
- N. SakamotoNSN. Sakamoto
- T. KuwataTKT. Kuwata
- A. KawazoeAKA. Kawazoe
- M. YoshidaMYM. Yoshida
- M. YuraMYM. Yura
- Y. MatsubaraYMY. Matsubara
- A. JubashiAJA. Jubashi
- S. SatoSSS. Sato
- S. UshiyamaSUS. Ushiyama
- Y. MiyashitaYMY. Miyashita
Open Access
- 2 August 2024
- journal article
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 5
Abstract
No abstract availableKeywords
Funding Information
- Meso Scale Diagnostics
- Roche
This publication has 20 references indexed in Scilit:
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancerESMO Open, 2024
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancerESMO Open, 2023
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapyGastric Cancer, 2022
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- Gastric cancerThe Lancet, 2020
- Japanese gastric cancer treatment guidelines 2018 (5th edition)Gastric Cancer, 2020
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010